ARISE (pAdsevonil in dRug-ResIStant Epilepsy)

A randomized, double-blind, placebo-controlled, dose finding study to evaluate the efficacy and safety of padsevonil as adjunctive treatment of focal-onset seizures in adult subjects with drug resistant epilepsy

  • This study focuses on evaluating the efficacy and safety of a drug on adults who suffer from focal-onset seizures with diagnosed drug-resistant epilepsy.

  • This drug focuses on adults whose seizures are not well controlled with the treatment they are on and serves as an add on drug.

  • These adults have continued to have uncontrolled focal-onset seizure despite treatment with at least 4 prior AED regimens.

  • Those taking GABA-A-ergic AEDs will be able to participate, but those taking Gaba-A-ergic drugs (Agonists (barbiturates) or Allosteric modulators (BSDs or non BZDs) more than twice a week are not able to participate.

  • This drug will be compared to a placebo, which is a drug that appears similar to the study drug, but does not contain the active ingredients.

  • The study will be conducted over a 24 week period and includes study visits to the site as required by the doctor.

  • You will be compensated for your time and participation.

Name *